NCT03077659 - Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

October 4, 2018

Study Completion Date

October 4, 2018

Conditions

Adenocarcinoma of the Prostate

Interventions

DRUG

NanoPac®

Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.

Trial Locations (1)

90033

University of Southern California, Los Angeles